Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Lung Cancer treatment details. Biologic therapy. Chemotherapy. Poznan University of Medical Sciences, Poznan, Poland

Survival: 10.1 months
Toxicity Grade: 5
Treatments: Biologic therapy
Country: Poland
City/State/Province: Poznan
Hospital: Poznan University of Medical Sciences
Journal: Link
Date: 10/2012

This phase 3 study involved platinum-pretreated patients with advanced or metastatic non-squamous non-small-cell lung cancer patients who were divided into two separate treatment groups. Group A had 457 patients with an average age of 59.6 years and 65.6% male. Group B consisted of 456 patients with an average age of 59.6 years and 66.9% male.

Patients in group A were treated with the chemotherapy agent docetaxel and the biologic therapy aflibercept, which is an inhibitor of the VEGF protein that interferes with tumor growth.

Patients in group B were treated with docetaxel and a placebo.

Treatment-related deaths due to neutropenic infections and pulmonary embolism were reported in group A. Grade 3 or higher kidney toxicity, fatigue, and stomatitis (inflammation of the lining of the GI tract) were also reported.

In group B, there were treatment-related deaths due to neutropenic infection and arterial thromboembolisms (blood clots). Grade 3 or higher fatigue and shortness of breath were also reported.

The median overall survival was 10.1 months for group A and 10.4 months for group B.

This study was supported by Sanofi, makers of aflibercept.

Correspondence: Dr. Rodryg Ramlau; email:

E-mail to a Friend Email Physician More Information